Steward Partners Investment Advisory’s Standard BioTools LAB Stock Holding History

Steward Partners Investment Advisory’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$823	Buy	+1,000	New	+$945	﹤0.01%	4412

Other funds holding LAB

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steward Partners Investment Advisory's LAB Position: Q2 2026 in Review

Steward Partners Investment Advisory opened a new position in Standard BioTools (LAB) in Q2 2026: 1,000 shares worth $823. The stake represents ﹤0.01% of the portfolio and ranks #4412 among its holdings.

128 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

Steward Partners Investment Advisory held 1,000 shares of Standard BioTools worth $823 as of Q2 2026.
Standard BioTools was a new Steward Partners Investment Advisory position in Q2 2026.
Standard BioTools made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #4412 holding.
128 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.